Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;9(4):1690-1698.
doi: 10.21037/tlcr.2019.11.33.

Multidisciplinary team care in advanced lung cancer

Anna Kowalczyk  1 , Jacek Jassem  1
Affiliations
Review

Multidisciplinary team care in advanced lung cancer

Anna Kowalczyk et al. Transl Lung Cancer Res. 2020 Aug.

Abstract

Lung cancer is the most common cause of cancer mortality globally. A vast majority of lung cancer cases are diagnosed at advanced stages. Management of advanced lung cancer requires several diagnostic and therapeutic procedures provided by various specialists. To optimise the entire diagnostic and therapeutic process, a concept of care provided simultaneously by a multidisciplinary team (MDT) has been developed and implemented in specialised centres worldwide. Observational studies suggest that integrated and coordinated care increases adherence to clinical guidelines, significantly shortens the interval from diagnosis to treatment, and may increase survival and quality of life (QoL). Prospective studies are warranted to assess the real impact of MDT on treatment outcomes and to further refine this approach.

Keywords: Multidisciplinary care; diagnosis; lung cancer; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr.2019.11.33). The series “Lung Cancer Multidisciplinary Care” was commissioned by the editorial office without any funding or sponsorship. JJ reports personal fees from AstraZeneca, personal fees and non-financial support from Roche, personal fees and non-financial support from Pfizer, personal fees from BMS, personal fees from MSD, personal fees from Takeda, outside the submitted work; The authors have no other conflicts of interest to declare.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. Walters S, Maringe C, Coleman MP, et al. ICBP Module 1 Working Group. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax 2013;68:551-64. 10.1136/thoraxjnl-2012-202297 - DOI - PubMed
    1. Molina JR, Yang P, Cassivi SD, et al. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc 2008;83:584-94. 10.1016/S0025-6196(11)60735-0 - DOI - PMC - PubMed
    1. Prades J, Remue E, van Hoof E, et al. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 2015;119:464-74. 10.1016/j.healthpol.2014.09.006 - DOI - PubMed
    1. Chen CH, Hsieh MC, Lao WT, et al. Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis. Am J Cancer Res 2018;8:1887-98. - PMC - PubMed